Definitive Healthcare Corp (DH)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Definitive Healthcare Corp. (DH) Q4 2024 Earnings Call Transcript
Definitive Healthcare Corp. (NASDAQ:DH ) Q4 2024 Results Conference Call February 27, 2025 5:00 PM ET Company Participants Matthew Ruderman - Investor Relations Kevin Coop - Chief Executive Officer Rick Booth - Chief Financial Officer Conference Call Participants Jared Haase - William Blair Hanna Lee - Bank of America Jenny Shen - BTIG David Grossman - Stifel Maxi Ma - Deutsche Bank Johnathan McCary - Raymond James Craig Hettenbach - Morgan Stanley Jeff Garro - Stephens Operator Welcome to Definitive Healthcare's Q4 2024 Earnings Call. [Operator Instructions] I would like to now turn the call over to your host.
Definitive Healthcare Corp. (DH) Q4 Earnings and Revenues Surpass Estimates
Definitive Healthcare Corp. (DH) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.07 per share a year ago.
A Dive Into Definitive Healthcare
Definitive Healthcare trades at a discount to the overall market based on P/E, and a new CEO with a focus on simplifying operations but faces declining profits and revenues. The company also has recently announced a new $100 billion stock buyback authorization and is seeing significant unlevered free cash flow. A first look at Definitive Healthcare follows in the paragraphs below.
Definitive Healthcare (DH) Surges 8.4%: Is This an Indication of Further Gains?
Definitive Healthcare (DH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Definitive Healthcare (DH) Moves to Buy: Rationale Behind the Upgrade
Definitive Healthcare (DH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down -5.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Definitive Healthcare (DH)
Definitive Healthcare (DH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Definitive Healthcare initiated with an Equal Weight at Stephens
Stephens initiated coverage of Definitive Healthcare with an Equal Weight rating and $5 price target. Definitive has "an impressive collection of data assets that have attracted a marquee customer base," as well as a track record of expanding enterprise relationships, but this is all "still in early stages of coming together as a single, unified platform," the analyst tells investors. The firm thinks investors need to see multiple, firm data points supporting a return to growth before re-rating the stock higher from here, the analyst added.
Surging Earnings Estimates Signal Upside for Definitive Healthcare (DH) Stock
Definitive Healthcare (DH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Definitive Healthcare Corp. (DH)) Q3 2024 Earnings Call Transcript
Definitive Healthcare Corp. (NASDAQ:DH ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Matt Ruderman - Investor Relations Kevin Coop - Chief Executive Officer Richard Booth - Chief Financial Officer Conference Call Participants Jenny Shen - BTIG George Hill - Deutsche Bank Anna Kruszenski - Barclays Bank Operator Welcome to Definitive Healthcare's Q3 2024 Earnings Call. Later we will conduct a question-and-answer session.
Definitive Healthcare Corp. (DH) Beats Q3 Earnings and Revenue Estimates
Definitive Healthcare Corp. (DH) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.09 per share a year ago.
Irenic Capital Management LP's Strategic Acquisition in Definitive Healthcare Corp
On September 30, 2024, Irenic Capital Management LP (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 6,413,185 shares of Definitive Healthcare Corp (DH, Financial). This transaction, executed at a price of $4.47 per share, marks a substantial increase in the firm's holdings in the healthcare sector, reflecting a strategic move to bolster its position in this industry.
Definitive Healthcare: Poor Near-Term Outlook, But New CEO May Change Things
DH remains a hold rating due to its poor near-term outlook and recent results. 2Q24 results show decelerating growth, client count decline, and an elongated sales cycle. New CEO Kevin Coop could be a game changer, but there is no reason to invest in DH at this point.
